circCAMSAP1 promotes osteosarcoma progression and metastasis by sponging miR-145-5p and regulating FLI1 expression.
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
05 Mar 2021
05 Mar 2021
Historique:
received:
21
05
2020
accepted:
16
12
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Osteosarcoma is the most common primary malignant bone tumor in adolescents. While chemotherapy combined with surgery can improve the prognosis of some patients, chemo-resistance is still a huge obstacle in osteosarcoma treatment. Accumulating evidence demonstrates that circular RNAs (circRNAs) are involved in cancer progression and metastasis, but their specific role in osteosarcoma remains mostly undescribed. In this study, we performed circRNA deep sequencing and identified 88 distinct circRNAs from a human osteosarcoma cell lines group (143B, HOS, SJSA, and U2OS) and the human osteoblast hFOB 1.19 (control). We found that circCAMSAP1, also named hsa_circ_0004338, is significantly upregulated in human osteosarcoma tissues and cell lines, and it is positively correlated with osteosarcoma development. Silencing of circCAMSAP1 effectively suppresses osteosarcoma cell growth, apoptosis, migration, and invasion. Furthermore, we validated that circCAMSAP1 functions in osteosarcoma tumorigenesis through a circCAMSAP1/miR-145-5p/friend leukemia virus integration 1 (FLI1) pathway. FLI1 promotes osteosarcoma tumorigenesis and miR-145-5p suppresses FLI translation. circCAMSAP1 directly sequesters miR-145-5p in the cytoplasm and inhibits its activity to suppress osteosarcoma tumorigenesis. Moreover, the regulatory role of circCAMSAP1 upregulation was examined and validated in rats. In summary, our findings provide evidence that circCAMSAP1 act as a "microRNA sponge" and suggest a new therapeutic target of human osteosarcoma.
Identifiants
pubmed: 33664993
doi: 10.1016/j.omtn.2020.12.013
pii: S2162-2531(20)30394-2
pmc: PMC7901030
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1120-1135Informations de copyright
© 2020.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Cell. 2016 Apr 7;165(2):289-302
pubmed: 27040497
Oncogene. 2000 Dec 18;19(55):6482-9
pubmed: 11175364
EMBO Rep. 2017 Sep;18(9):1646-1659
pubmed: 28794202
Ann Rheum Dis. 2019 Jun;78(6):826-836
pubmed: 30923232
Eur J Pharm Sci. 2018 Oct 15;123:28-42
pubmed: 30010029
Oncotarget. 2016 Jul 5;7(27):42241-42251
pubmed: 27304058
Leukemia. 2009 Jul;23(7):1311-9
pubmed: 19282832
J Clin Oncol. 1997 Jan;15(1):76-84
pubmed: 8996127
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Comp Neurol. 2012 Apr 15;520(6):1301-17
pubmed: 22095662
Cancer Sci. 2004 Aug;95(8):626-33
pubmed: 15298723
Nat Struct Mol Biol. 2015 Mar;22(3):256-64
pubmed: 25664725
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5752-6
pubmed: 8516324
PLoS One. 2012;7(2):e30733
pubmed: 22319583
Mol Ther. 2020 Mar 4;28(3):914-928
pubmed: 31951832
Sarcoma. 2012;2012:627254
pubmed: 22685381
Nat Neurosci. 2015 Apr;18(4):603-610
pubmed: 25714049
Cancer Res. 1992 Oct 15;52(20):5833-7
pubmed: 1394211
Cell Death Dis. 2020 Jan 6;11(1):18
pubmed: 31907361
Transl Oncol. 2014 Aug;7(4):493-502
pubmed: 25171891
Cancer Med. 2018 Aug;7(8):3548-3560
pubmed: 29869379
Methods Mol Biol. 2019;1870:137-149
pubmed: 30539552
Nat Commun. 2016 Apr 06;7:11215
pubmed: 27050392
Mol Cell Biol. 2000 Aug;20(15):5643-52
pubmed: 10891501
Autophagy. 2020 Apr;16(4):659-671
pubmed: 31232177
Cell Cycle. 2019 Jun;18(11):1281-1291
pubmed: 31116090
Cancer Res. 2018 Sep 1;78(17):4812-4825
pubmed: 29967262
Mol Cancer. 2019 Jun 22;18(1):111
pubmed: 31228937
Oncotarget. 2017 Jun 27;8(26):41975-41987
pubmed: 28410216
Mol Ther Nucleic Acids. 2019 Sep 6;17:669-677
pubmed: 31400609
Nucleic Acids Res. 2006 May 08;34(8):e63
pubmed: 16682442
Oncotarget. 2017 Dec 20;9(32):22288-22300
pubmed: 29854278
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Cell Biosci. 2019 Nov 29;9:94
pubmed: 31798828
Clin Orthop Relat Res. 2008 Sep;466(9):2114-30
pubmed: 18563507
Clin Cancer Res. 2019 Feb 15;25(4):1302-1317
pubmed: 30429198
Genome Biol. 2015 Jan 13;16:4
pubmed: 25583365
Mol Cancer. 2018 Dec 4;17(1):170
pubmed: 30514309
Mol Cancer. 2018 Nov 19;17(1):160
pubmed: 30454010
Cancer Lett. 2019 Sep 28;460:128-138
pubmed: 31207319
Biomed Pharmacother. 2019 Jan;109:226-232
pubmed: 30396080
RNA. 2013 Feb;19(2):141-57
pubmed: 23249747
Cancer. 1999 Oct 15;86(8):1602-8
pubmed: 10526292
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Paediatr Drugs. 2008;10(5):315-27
pubmed: 18754698
Biomed Pharmacother. 2018 Nov;107:860-866
pubmed: 30142548
Nat Biotechnol. 2014 May;32(5):453-61
pubmed: 24811520
J Neurosci Res. 2009 Feb;87(2):503-13
pubmed: 18756519
J Cell Mol Med. 2018 Dec;22(12):6112-6121
pubmed: 30324718
Int J Oncol. 2014 May;44(5):1678-84
pubmed: 24603804
Biosci Rep. 2019 May 17;39(5):
pubmed: 31036604
Nat Immunol. 2019 Feb;20(2):183-194
pubmed: 30643264
F1000Res. 2016 Nov 25;5:2767
pubmed: 27990273
Mol Cancer. 2019 Apr 2;18(1):73
pubmed: 30940151
Theranostics. 2019 May 26;9(12):3526-3540
pubmed: 31281495
Cancer Lett. 2017 Oct 28;407:32-44
pubmed: 28823959